-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 H7aHVhLZ64uGgas1dlotejJeKbv4gyRWxvw7B8ENI5a2ugf33Obck8UW+H5Fb36s
 tKD6O1H+xzEdnAMGlM4CXQ==

<SEC-DOCUMENT>0000012208-03-000009.txt : 20030730
<SEC-HEADER>0000012208-03-000009.hdr.sgml : 20030730
<ACCEPTANCE-DATETIME>20030729194117
ACCESSION NUMBER:		0000012208-03-000009
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20030728
ITEM INFORMATION:		Other events
FILED AS OF DATE:		20030730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		03809796

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>r8kjul29.txt
<TEXT>







                 SECURITIES AND EXCHANGE COMMISSION
                      Washington, D.C.  20549





                              FORM 8-K




                           CURRENT REPORT
                 Pursuant to Section 13 or 15(d) of
                The Securities Exchange Act of 1934


                   Date of Report:  July 28, 2003
                 (Date of earliest event reported)


                     BIO-RAD LABORATORIES, INC.
    ________________________________________________________________
       (exact name of registrant as specified in its charter)


                         Commission File: 1-7928

        Delaware                                  94-1381833
    ________________________________________________________________
      (State or other                         (I.R.S. Employer
      jurisdiction of                        Identification No.)
     incorporation or
       organization)



                       1000 Alfred Nobel Dr.
                     Hercules, California 94547
    ________________________________________________________________
      (Address of Principal executive offices, including zip code)

                           (510) 724-7000
    ________________________________________________________________
        (Registrant's telephone number, including area code)




    <PAGE>

    ITEM 5.     OTHER EVENTS AND REGULATION FD DISCLOSURE.

         On July 28, 2003, Bio-Rad Laboratories, Inc. issued a press release
    announcing that it is offering, subject to market and other conditions,
    up to $200,000,000 aggregate principal amount of new senior subordinated
    notes in a private offering.  A copy of the press release is attached
    hereto as Exhibit 99.1 and is incorporated herein by reference.


    ITEM 12.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

         The information in Item 12 of this Report, including Exhibit 99.2
    attached hereto, is being furnished pursuant to Item 12 of Form 8-K.
    Consequently, it is not deemed "filed" for the purposes of Section 18 of
    the Securities and Exchange Act of 1934, as amended, or otherwise subject
    to the liabilities of that section. It may only be incorporated by
    reference in another filing under the Exchange Act or Securities Act of
    1933, as amended, if such subsequent filing specifically references this
    Form 8-K.

         On July 28, 2003, Bio-Rad Laboratories, Inc. announced its results
    of operations and financial condition as of and for the second quarter
    ended June 30, 2003.  A copy of the press release is attached hereto as
    Exhibit 99.2 and is incorporated herein by reference.

    <PAGE>

    ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND
    EXHIBITS.


         (c)  Exhibits

    Exhibit
    Number                            Description

    99.1   Press Release announcing private offering of Bio-Rad Laboratories,
           Inc., dated July 28, 2003.
    99.2   Press Release for second quarter financial results of Bio-Rad
           Laboratories, Inc., dated July 28, 2003. This exhibit is being
           furnished pursuant to Item 12 of Form 8-K.

    <PAGE>





                                   SIGNATURES



         Pursuant to the requirements of the Securities Exchange Act of 1934,
    the Registrant has duly caused this report to be signed on its behalf by
    the undersigned hereunto duly authorized.


                                       BIO-RAD LABORATORIES,INC.



    Date:  July 29, 2003               By: /s/ Sanford S. Wadler
                                          Vice President
                                          General Counsel and Secretary


    <PAGE>


                                EXHIBIT INDEX

    Exhibit
    Number                       Description

    99.1   Press Release announcing private offering of Bio-Rad Laboratories,
           Inc., dated July 28, 2003.
    99.2   Press Release for second quarter financial results of Bio-Rad
           Laboratories, Inc., dated July 28, 2003. This exhibit is being
           furnished pursuant to Item 12 of Form 8-K.

    <PGAE>





</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>ex991.txt
<TEXT>



    EXHIBIT 99.1

    PRESS RELEASE


                      Bio-Rad Announces Private Offering
                 of $200 Million of Senior Subordinated Notes

    HERCULES, CA - July 28, 2003 - Bio-Rad Laboratories,Inc. (AMEX: BIO and
    BIO.B), a multinational manufacturer and distributor of life science
    research products and clinical diagnostics, announced today that it is
    offering, subject to market and other conditions, up to $200 million
    aggregate principal amount of senior subordinated notes in a private
    offering. The Company intends to use a portion of the net proceeds from
    this offering to fund the purchase of its outstanding 11 5/8% Senior
    Subordinated Notes due 2007 pursuant to the tender offer announced by the
    Company on July 17, 2003.

         The new senior subordinated notes have not been registered under the
    Securities Act of 1933, as amended, or applicable state securities laws,
    and will be offered only to qualified institutional buyers in reliance on
    Rule 144A and in offshore transactions pursuant to Regulation S under the
    Securities Act of 1933, as amended. Unless so registered, the new senior
    subordinated notes may not be offered or sold in the United States except
    pursuant to an exemption from the registration requirements of the
    Securities Act and applicable state securities laws.

         This press release shall not constitute an offer to sell or the
    solicitation of an offer to buy these securities, nor shall there be any
    sale of these securities in any state in which such offer, solicitation or
    sale would be unlawful prior to registration or qualification under the
    securities laws of any such state.

         Various statements made within this press release may constitute
    "forward-looking statements" for purposes of the  Securities and Exchange
    Commission's "safe harbor" provisions under the Private Securities
    Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange
    Act of 1934. The forward-looking statements contained herein involve risks
    and uncertainties that could cause results to differ materially from the
    Company's expectations.

    <PAGE>




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>4
<FILENAME>ex992.txt
<TEXT>





    EXHIBIT 99.2

    PRESS RELEASE



       Bio-Rad Laboratories Reports Second Quarter Financial Results -
           Company Reports Growth Across Both Business Segments

    HERCULES, CA -  July 28, 2003 - Bio-Rad Laboratories, Inc. (AMEX:BIO and
    BIO.B), a multinational manufacturer and distributor of life science
    research products and clinical diagnostics, announced that second quarter
    net sales increased by 13.4 percent to $243.5 million compared to $214.7
    million in the same period last year. Net income for the quarter grew
    29.1 percent to $21.0 million compared to $16.2 million in the second
    quarter of 2002.

         Net sales for the first two quarters grew by 15.2 percent to $489.5
    million as compared to the same period last year.  Normalizing for the
    impact of currency effects, six month year-over-year growth was 5.3
    percent.  At 57.0 percent, gross margin for the first two quarters was down
    slightly compared to 57.3 percent in the same period of 2002.  Net income
    for the six-month period was $47.3 million, or $1.87 per share, a 33.6
    percent increase compared to the $35.0 million, or $1.40 per share reported
    in the corresponding period of last year.

          Second Quarter Highlights

          -  Overall Company sales grew by 13.4 percent for the quarter, or
             by 4.0 percent on a currency-neutral basis.
          -  Second quarter basic earnings were up 27.7 percent to $0.83 per
             share, or $0.80 per share on a diluted basis,compared to basic
             earnings per share of $0.65 and diluted earnings per share of
             $0.62 in the second quarter of last year.
          -  For the quarter, sales increased by 13.9 percent for the Clinical
             Diagnostics segment and by 13.5 percent for the Life Science
             segment compared to second quarter 2002 results.

         The Clinical Diagnostics segment reported sales of $127.3 million for
    the quarter, a 13.9 percent increase as compared to the same quarter last
    year. Exclusive of currency effects, this growth was due to solid
    performance in several areas including quality controls, blood virus
    screening, and diabetes monitoring.  During the quarter, the Company began
    introduction of its new D-10(TM) diabetes testing system and received FDA
    clearance for its Aspergillus test, which is the first such test available
    in the U.S. market.

         The Life Science segment's sales grew in the second quarter by 13.5
    percent to $114.3 million as compared to the same period last year.  Apart
    from currency, the drivers of growth in this segment were the nucleic acid
    amplification, microarray, and electrophoresis product categories, as well
    as products directed at biopharmaceutical production.


    <PAGE>

         "We are pleased to report solid financial performance for the quarter,
    balanced across our Life Science and Clinical Diagnostics segments" said
    Norman Schwartz,President and Chief Executive Officer.  "During the second
    half of the year, our focus will be on the introduction of a number of new
    products, improving operating efficiencies and restructuring our
    financing."

         The Company recently announced a tender offer and consent solicitation
    for its remaining $88.7 million 11 5/8% senior subordinated notes due 2007.
    In addition, Bio-Rad is currently in discussions with a bank syndicate to
    amend and restate its credit facility to provide for a $150 million
    revolving facility.

         Management will discuss these results in a conference call at 5:30
    a.m. PT (8:30 a.m. ET) July 28, 2003. Interested parties can access the
    call by dialing (800) 967-7134, or by accessing the web cast at
    http://www.bio-rad.com.  A replay of the call will be available at
    (719)457-0820, access number 234822, for 3 days following the call, and
    the web cast can be accessed at http://www.bio-rad.com for 30 days.

         Bio-Rad Laboratories, Inc. (www.bio-rad.com) is a multinational
    manufacturer and distributor of life science research products and clinical
    diagnostics. It is based in Hercules, California, and serves more than
    70,000 research and industry customers worldwide through a network of more
    than 30 wholly owned subsidiary offices.

         Various statements made within this press release may constitute
    "forward-looking statements" for purposes of the Securities and Exchange
    Commission's "safe harbor" provisions under the Private Securities
    Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange
    Act of 1934. The forward-looking statements contained herein involve risks
    and uncertainties that could cause results to differ materially from the
    Company's expectations.

                       Bio-Rad Laboratories, Inc.
                          Second Quarter 2003
               Condensed Consolidated Statements of Income

                  (in thousands, except per share data)
                             (unaudited)

                                   Three Months         Six Months
                                  Ended June 30,      Ended June 30,
                                  2003      2002      2003      2002
                                  ----      ----      ----      ----

    Net Sales                   $243,507  $214,660  $489,476   $424,842
    Cost of Goods Sold           107,103    92,386   210,359    181,228
                                --------  --------  --------   --------
    Gross Profit                 136,404   122,274   279,117    243,614


    Selling, General and
      Administrative Expense      79,026    69,486   156,185    135,222
    Product Research and
      Development Expense         22,731    19,806    44,119     40,047
    Interest Expense               3,696     5,982     8,347     11,536
    Foreign Exchange Losses, net     554     2,059     1,323      2,809
    Other (Income) Expense, net     (880)     (489)   (1,484)       962
                                --------  --------  --------   --------
    Income Before Taxes           31,277    25,430    70,627     53,038

    Provision for income taxes   (10,321)   (9,198)  (23,307)   (18,033)
                                --------  --------  --------   --------
    Net Income                   $20,956   $16,232   $47,320    $35,005
                                ========  ========  ========   ========

    Basic earnings per share       $0.83     $0.65     $1.87      $1.40
                                ========  ========  ========   ========
    Weighted average common       25,386    25,098    25,336     25,015
      shares                    ========  ========  ========   ========
    Diluted earnings per share     $0.80     $0.62     $1.81      $1.35
                                ========  ========  ========   ========
    Adjusted weighted average     26,341    26,085    26,214     25,951
      shares                    ========  ========  ========  =========


    <PAGE>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
